<DOC>
	<DOCNO>NCT00000826</DOCNO>
	<brief_summary>To determine effect fluconazole either rifabutin clarithromycin , alone combination , pharmacokinetics first sulfamethoxazole-trimethoprim dapsone HIV-infected patient . Although prophylaxis one opportunistic infection emerge common clinical practice patient advance HIV disease , little know possible adverse drug interaction . The need exist define pharmacokinetics pharmacodynamic adverse interaction many combination prophylactic regimen may prescribe .</brief_summary>
	<brief_title>Effect Fluconazole , Clarithromycin , Rifabutin Pharmacokinetics Sulfamethoxazole-Trimethoprim Dapsone Their Hydroxylamine Metabolites</brief_title>
	<detailed_description>Although prophylaxis one opportunistic infection emerge common clinical practice patient advance HIV disease , little know possible adverse drug interaction . The need exist define pharmacokinetics pharmacodynamic adverse interaction many combination prophylactic regimen may prescribe . In Part A , patient receive sulfamethoxazole-trimethoprim ( SMX/TMP ) alone 2 week , combination fluconazole , rifabutin , drug , 2-week period randomly assign order . Patients Part B receive regimen except clarithromycin substitute rifabutin . In Part C , patient receive dapsone alone 2 week , combination fluconazole , rifabutin , drug manner Part A . Part D patient receive regimen Part C , except clarithromycin substitute rifabutin . Patients follow every 2 week .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Trimethoprim , Sulfamethoxazole Drug Combination</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<mesh_term>Sulfamethoxazole</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Trimethoprim</mesh_term>
	<mesh_term>Clarithromycin</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<criteria>Inclusion Criteria Concurrent Medication : Allowed : Antiretroviral therapy provide patient stable dose least 4 week prior study entry . Methadone drug abuse program provide patient stable dose least 4 week prior study . Patients must : HIV infection . CD4 count &gt; = 200 cells/mm3 . No active opportunistic infection . Prior Medication : Allowed : Antiretroviral therapy . Methadone drug abuse therapy . Exclusion Criteria Coexisting Condition : Patients follow symptoms condition exclude : Suspicion gastrointestinal malabsorption problem ( discretion investigator ) . Known hypersensitivity dapsone , SMX , sulfonamide , trimethoprim , clarithromycin , rifabutin rifamycins , fluconazole , azoles . G6PD deficiency methemoglobinemia ( Part C D patient ) . Concurrent Medication : Excluded : Cytolytic agent . Amiodarone . Anesthetics , general . Astemizole . Azithromycin . Barbiturates . Carbamazepine . Cimetidine . Ciprofloxacin . Cisapride . Clarithromycin ( except require study ) . Clotrimazole . Dexamethasone . Disulfiram . Erythromycin . Fluoroquinolones . Fluoxetine . Gestodene . Hydrochlorothiazide . Hypoglycemics , oral . Isoniazid . Itraconazole . Ketoconazole . Levomepromazine . Loratadine . MAO inhibitor . Methoxsalen . Miconazole . Nafcillin . Narcotic analgesic . Naringenin . Nifedipine . Norethindrone . Pentazocine . Phenothiazines . Phenytoin . Protease inhibitor . Quinidine . Ranitidine . Rifabutin ( except require study ) . Rifampin . Sedative hypnotic . Sulfaphenazole . Terfenadine . Tranquilizers ( unless allow investigator ) . Tricyclic tetracyclic antidepressant . Troleandomycin . Warfarin . Concurrent Treatment : Excluded : Radiation therapy . Prior Medication : Excluded : Cytolytic agent within 5 year prior study entry . Rifabutin and/or rifampin within 4 week prior study entry . Fluconazoles azoles within 4 week prior study entry . Glutathione , glutathione precursor , relate prodrugs within 2 week prior study entry . Excluded within 72 hour prior study entry : Amiodarone . Anesthetics , general . Astemizole . Azithromycin . Cimetidine . Ciprofloxacin . Cisapride . Clarithromycin . Dexamethasone . Disulfiram . Erythromycin . Fluoroquinolones . Fluoxetine . Hydrochlorothiazide . Hypoglycemics , oral . Isoniazid . Levomepromazine . Loratadine . MAO inhibitor . Methoxsalen . Nafcillin . Narcotic analgesic . Naringenin . Nifedipine . Norethindrone . Pentazocine . Phenothiazines . Phenytoin . Protease inhibitor . Quinidine . Ranitidine . Sedative hypnotic . Sulfaphenazole . Terfenadine . Tranquilizers ( unless allow investigator ) . Troleandomycin . Warfarin . Excluded within 4 week prior study entry : Barbiturates . Carbamazepine . Clotrimazole . Gestodene . Itraconazole . Ketoconazole . Miconazole . Omeprazole . Rifabutin . Rifampin . Tricyclic tetracyclic antidepressant . Prior Treatment : Excluded : Blood transfusion within 1 week prior study entry . Radiation therapy within 5 year prior study entry . Active drug alcohol abuse dependence would preclude completion study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Rifabutin</keyword>
	<keyword>Trimethoprim-Sulfamethoxazole Combination</keyword>
	<keyword>AIDS-Related Opportunistic Infections</keyword>
	<keyword>Dapsone</keyword>
	<keyword>Drug Interactions</keyword>
	<keyword>Fluconazole</keyword>
	<keyword>Acquired Immunodeficiency Syndrome</keyword>
	<keyword>AIDS-Related Complex</keyword>
	<keyword>Clarithromycin</keyword>
	<keyword>Sulfamethoxazole-Trimethoprim</keyword>
</DOC>